Nova Ltd vs uniQure N.V. Ordinary Shares — how do they compare? Nova Ltd trades at $329.39 (market cap $10.89B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Nova Ltd is far larger — about 7.4× uniQure N.V. Ordinary Shares's market cap, and Nova Ltd is more actively traded (416,153 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold Nova Ltd for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NVMI | QURE | |
|---|---|---|
Market Cap | $10.89B | $1.48B |
Volume | 416,153 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $605.65 | $70.59 |
52-Week Low | $275.78 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.67B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
NVMI trades at $342.37, up 0.58% on the day, with a bearish technical signal driven by moving averages but supported by strong fundamentals including a 28.84% net income margin and three consecutive quarterly earnings beats. The stock is positioned near its pivot point of $344, with immediate support at $336. Revenue growth is projected to increase from $881 million in 2025 to $937 million in 2026, though net cash flow turned negative in 2026.
The outlook remains positive given the 85.7% analyst buy rating and a consensus price target of $556.50, implying significant upside. Key risks include high valuation multiples like a P/E of 42.64 and negative cash flow trends, but the company's tool-of-record status in AI chip packaging provides a durable growth catalyst.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →